Clinical trial
An Open-Label, Randomized Study to Determine the Impact of Antiretroviral Treatment in HCV/HIV-Coinfected Subjects With High CD4+ Cell Count on the Efficacy of Hepatitis C Treatment With Pegylated Interferon Alfa-2A and Ribavirin
NCT00100581 is registered in ClinicalTrials.gov with National Institute of Allergy and Infectious Diseases (NIAID) as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-Label, Randomized Study to Determine the Impact of Antiretroviral Treatment in HCV/HIV-Coinfected Subjects With High CD4+ Cell Count on the Efficacy of Hepatitis C Treatment With Pegylated Interferon Alfa-2A and Ribavirin
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- Phase
- Not applicable
- Overall status
- Completed
- Start date
- Not reported
- Completion date
- January 31, 2007
- Enrollment
- 2 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.